DE

460.88

+0.05%↑

CTAS

198.8

-0.16%↓

FDX

240.24

-0.95%↓

PAYX

126.51

-0.29%↓

CPRT

44.93

+1.65%↑

DE

460.88

+0.05%↑

CTAS

198.8

-0.16%↓

FDX

240.24

-0.95%↓

PAYX

126.51

-0.29%↓

CPRT

44.93

+1.65%↑

DE

460.88

+0.05%↑

CTAS

198.8

-0.16%↓

FDX

240.24

-0.95%↓

PAYX

126.51

-0.29%↓

CPRT

44.93

+1.65%↑

DE

460.88

+0.05%↑

CTAS

198.8

-0.16%↓

FDX

240.24

-0.95%↓

PAYX

126.51

-0.29%↓

CPRT

44.93

+1.65%↑

DE

460.88

+0.05%↑

CTAS

198.8

-0.16%↓

FDX

240.24

-0.95%↓

PAYX

126.51

-0.29%↓

CPRT

44.93

+1.65%↑

Search

Ocugen Inc

Closed

1.78 1.71

Overview

Share price change

24h

Current

Min

1.76

Max

1.87

Key metrics

By Trading Economics

Income

611K

-15M

Sales

-108K

1.4M

Profit margin

-1,073.489

Employees

95

EBITDA

724K

-13M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+367.03% upside

Dividends

By Dow Jones

Next Earnings

7 lis 2025

Market Stats

By TradingEconomics

Market Cap

250M

568M

Previous open

0.07

Previous close

1.78

Technical Score

By Trading Central

Confidence

Strong Bearish Evidence

Ocugen Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

8 paź 2025, 20:45 UTC

Earnings

Costco Wholesale Sales Climb in September, Early October

8 paź 2025, 20:12 UTC

Major Market Movers
Acquisitions, Mergers, Takeovers

TaskUs Shares Fall After Holders Reject Take-Private Deal

8 paź 2025, 16:39 UTC

Major Market Movers

Mining Shares Rise as Gold Prices Soar

8 paź 2025, 23:45 UTC

Market Talk

Nikkei May Rise on Weaker Yen -- Market Talk

8 paź 2025, 23:43 UTC

Market Talk

Gold Falls on Possible Profit-Taking -- Market Talk

8 paź 2025, 23:18 UTC

Acquisitions, Mergers, Takeovers

JD Logistics to Finance Acquisition Using Internal Funds

8 paź 2025, 23:17 UTC

Acquisitions, Mergers, Takeovers

JD Logistics to Buy On-Demand Delivery Services Business for US$270.0M

8 paź 2025, 23:16 UTC

Acquisitions, Mergers, Takeovers

JD Logistics to Buy JD.com's On-Demand Delivery Services Business Dajiang and Dasheng

8 paź 2025, 21:54 UTC

Market Talk
Earnings

James Hardie Could Beat Annual Earnings Goal -- Market Talk

8 paź 2025, 21:30 UTC

Market Talk

Boab Metals Bull Delivers Second Upgrade in a Month -- Market Talk

8 paź 2025, 21:26 UTC

Market Talk
Earnings

Transurban's 1Q Traffic Growth Beats Hopes -- Market Talk

8 paź 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

8 paź 2025, 19:15 UTC

Market Talk

Geopolitical Risk Supports Gains in Oil Futures -- Market Talk

8 paź 2025, 19:01 UTC

Market Talk

U.S. Natural Gas Futures Pull Back Ahead of Storage Data -- Market Talk

8 paź 2025, 18:47 UTC

Market Talk

Coca-Cola North America Sales Buoy International Weakness -- Market Talk

8 paź 2025, 18:46 UTC

Acquisitions, Mergers, Takeovers

TaskUs: Neither Party Will Be Required to Pay Termination Fee as Result of Planned Mutual Decision to Terminate

8 paź 2025, 18:46 UTC

Acquisitions, Mergers, Takeovers

TaskUs Will Remain a Publicly Traded Co >TASK

8 paź 2025, 18:46 UTC

Acquisitions, Mergers, Takeovers

TaskUs Does Not Plan to Convene Another Special Meeting of Stockholders >TASK

8 paź 2025, 18:45 UTC

Acquisitions, Mergers, Takeovers

TaskUs Didn't Receive Votes Necessary to Approve Transaction Agreement With Affil of Blackstone >TASK

8 paź 2025, 18:07 UTC

Market Talk

Mexico's Inflation Seen Edging Up in September -- Market Talk

8 paź 2025, 16:20 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Energy & Utilities Roundup: Market Talk

8 paź 2025, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

8 paź 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

8 paź 2025, 15:57 UTC

Market Talk

Oil Rises Despite U.S. Crude Stockpiles Build -- Market Talk

8 paź 2025, 15:56 UTC

Market Talk

Teck Resources' Chile Mine Issues Appear Transitory -- Market Talk

8 paź 2025, 15:53 UTC

Market Talk

Argentine Sovereign Debt Seen as Attractive -- Market Talk

8 paź 2025, 15:44 UTC

Acquisitions, Mergers, Takeovers

Staar Surgical: Broadwood's Proposal to Vote Down Merger Could Allow It to Take Control Without Paying Any Premium

8 paź 2025, 15:44 UTC

Acquisitions, Mergers, Takeovers

Staar Surgical Board and Management Disagree With Recommendation Issued by Glass Lewis >STAA

8 paź 2025, 15:43 UTC

Acquisitions, Mergers, Takeovers

STAAR Surgical Board Reiterates Unanimous Recommendation Holders Vote for Alcon Merger

8 paź 2025, 15:42 UTC

Acquisitions, Mergers, Takeovers

Oracle Is a Buy-the-Dip Opportunity, Analyst Says. How the Stock Could Rise 23%. -- Barrons.com

Peer Comparison

Price change

Ocugen Inc Forecast

Price Target

By TipRanks

367.03% upside

12 Months Forecast

Average 8.5 USD  367.03%

High 15 USD

Low 4 USD

Based on 4 Wall Street analysts offering 12 month price targets forOcugen Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

4 ratings

4

Buy

0

Hold

0

Sell

Technical Score

By Trading Central

0.6818 / 0.74Support & Resistance

Short Term

Strong Bearish Evidence

Intermediate Term

Strong Bullish Evidence

Long Term

No Evidence

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Ocugen Inc

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.
help-icon Live chat